The company's customer wins this year suggest more revenue expansion to come. In fact, C3.ai forecasts fiscal 2026 sales to ...

The company developed its own custom chips, Trainium and Inferentia, which can offer cost-optimal alternatives to traditional ...

This has led to strong growth for the company, with C3.ai's revenue rising 25% year over year in fourth-quarter fiscal year 2025 (ending April 30). It also expects strong growth for FY 2026, with ...

Upgrade your portfolio! C3.ai is a strong buy with explosive growth, top-tier partnerships, and AI exposure at a discount.

M&A is back is in style again under President Donald Trump. That’s good news for investors in stocks such as C3.ai, Viking ...

I've been writing about the LG C3 OLED TV since its release in 2023, and it has consistently been a best-seller, thanks to ...

Investing.com -- Teleperformance (EPA: TEPRF) shares plunged more than 16% on Friday after the company cut its full-year revenue outlook, reported weaker-than-expected margins and missed earnings ...

Growth boosts valuation multiples, but it doesn’t always last forever. Companies that cannot maintain it are often penalized ...

Apellis Pharmaceuticals Inc. (NASDAQ:APLS) is one of the biotech stocks to buy according to Wall Street analysts.

Tempus AI offers a strong business model with AI-driven genomic data, resilient demand, and significant growth prospects.

The stock rallies as C3.ai touts enterprise AI momentum, but rising pressure from rivals puts its niche to the test.

The new AI-focused ETF is putting your money where its mouth is, so to speak, by utilizing the very technology it's investing ...